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Smear-negative tuberculosisAspergillomas are often misdiagnosed as tuberculosis (TB) in developing countries where
the prevalence of TB is high, hemoptysis is often equated with TB, and most patients are
diagnosed clinically. This report describes the case of a patient being treated for smear-
negative TB who presented with hemoptysis and was found to have an aspergilloma.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction to our hospital for further management of massive hemopty-Aspergillomas are mass-like fungus balls that are typically
composed of Aspergillus fumigatus, and represent a non-
invasive form of pulmonary aspergillosis. Aspergillomas
occur in patients with structurally abnormal lungs, with
pre-existing cavities. This case report highlights an evasive
clinical condition with profound diagnostic and treatment
challenges particularly in developing countries.
Case report
In July 2013, a 38-year-old Ghanaian male on his 3rd week of
treatment for smear-negative tuberculosis (TB) was referredsis. He had noticed a small amount of hemoptysis about
1 month prior to his current visit along with weight loss,
low-grade fevers, and night sweats. At that time, he reported
to a district clinic and was started empirically on rifampicin,
isoniazid, pyrazinamide, and ethambutol. He also reported a
5-year history of unproductive cough. Although he had only
minimal exposure to cigarettes (<1 pack in his lifetime), he
had been exposed to second-hand smoke for 17 years. The
patient was originally from Salaga, Ghana, had been living
in Niger for nearly 20 years, and traveled frequently through
the desert and to Mali and Ghana.
The patient stated that his first experience of pulmonary
symptoms occurred 7 years earlier. In April 2006, the patientt Avenue,
gy, Private
Fig. 1 – (A) Chest radiograph showing fungal ball in the left apical lung taken at initial diagnosis; (B) 5 months into treatment
with 200 mg of daily itraconazole showing the aspergilloma.
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sweats, weight loss, and a cough productive of mucoid
sputum without hemoptysis. At presentation, the patient
weighed 40 kg. He had attempted unsuccessfully to treat his
symptoms at homewith antitussives, antimalarials, and mul-
tivitamins. Human immunodeficiency virus (HIV) screening
test result was negative and sputum for acid-fast bacilli
(AFB) was negative on three occasions. Chest radiographs
were performed, and based on those results he was given a
clinical diagnosis of TB. He completed a 2-month course of
streptomycin, isoniazid, rifampicin, and pyrazinamide fol-
lowed by 6 months of isoniazid and thiacetazone. At his
follow-up appointment in November 2006, he had a 29-kg
weight gain and resolution of his signs and symptoms.
The patient remained well until March 2008 when he pre-
sented with a mucopurulent cough, low-grade fever, night
sweats, and left-sided chest pain. Radiological findings were
suggestive of TB; however, further testing did not support this
diagnosis. His sputum smears were negative for AFB andFig. 2 – Chest computed tomography scan showing bilateral apica
thick-walled cavity with a solid intracavity mass with air crescbacterial growth; erythrocyte sedimentation rate and full
blood count were both within normal limits. Physical exami-
nation was unremarkable and demonstrated awell-appearing
middle-aged man with a clinically clear chest. He was
ultimately diagnosed with resolving atypical pneumonia, pre-
scribed analgesics for left-sided chest pain, and sent home.
His constitutional symptoms ultimately resolved, but he
continued to suffer from a nonproductive cough. In August
2009, he presented for evaluation of persistent cough. Sputum
AFB smearswere negative, and the patient was reassured that
he did not have TB. As the underlying cause for his cough
could not be determined, the patient was prescribed 1 week
of empiric amoxicillin/clavulanate. Despite the antibiotics,
his cough never resolved.
In June 2013, he noticed worsening of his usual cough
along with weight loss, low-grade fever, night sweats, and
minimal hemoptysis. He reported to a district hospital where
he was started on a second course of first-line anti-TB medi-
cation (rifampicin, isoniazid, pyrazinamide, and ethambutol).l post-tuberculosis lung fibrosis and a left apical 5.5  5.4-cm2
ent sign. (A) Lung; (B) mediastinal window.
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 2 3 5 –2 3 9 237There was no improvement in his symptoms, and 3 weeks
into treatment he was rushed to a private clinic after three
episodes of massive hemoptysis (about 200–300 mL of blood
during each episode). He was referred to our hospital with a
presumptive diagnosis of smear-negative TB and a differen-
tial diagnosis of histoplasmosis.
After reviewing the patient’s history and obtaining chest
radiographs (Fig. 1A), the infectious disease physician at
our hospital made a clinical diagnosis of aspergilloma and
initiated itraconazole while continuing the anti-TB medica-
tions. A medical review 2 weeks later showed marked
improvement in the patient’s symptoms and cessation of
his hemoptysis. After 5 months of itraconazole, chest radio-
graph still showed a well-circumscribed lesion in the left
upper zone (Fig. 1B). Chest computed tomography (CT) scan
at that time showed bilateral apical post-TB lung fibrosis
and a left apical 5.5  5.4-cm2 thick-walled cavity with a solid
intracavity mass with air crescent sign (Fig. 2A and B). After
2 years and 4 months of itraconazole, he had clinically
improved except for occasional dry cough and left-sided
chest pains.
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for review
by the Editor of this journal.
Discussion
Background information
Although it is clear that the global burden of fungal infections
– such as those caused by Aspergillus spp. – is increasing, the
exact magnitude of the problem remains unknown [1–3]. This
surge has been attributed to HIV/AIDS, TB, chronic obstruc-
tive pulmonary disease, the growing use of immunosuppres-
sive therapies, and a host of other conditions [4]. Globally, it is
estimated that 1.2 million people have chronic pulmonary
aspergillosis (CPA) as a sequel to TB, with Africa, Western
Pacific, and South-East Asia being the most affected [5].
Aspergilloma is one of several disease manifestations of
CPA and involves the saprophytic growth of Aspergillus spp.
such as Aspergillus fumigatus in the lung, most commonly in
apical lung cavities.
The diagnosis of aspergilloma can be elusive in developing
countries with a high prevalence of TB because hemoptysis is
often equated with TB without consideration of other differ-
ential diagnoses such as aspergilloma [5,6]. For this reason,
the actual disease burden of aspergilloma in sub-Saharan
Africa as well as its impact on morbidity is unknown [6]. In
cases where sputum for AFB is negative or patients fail to
improve on standard therapy, patients may be started on
treatment for smear-negative or drug-resistant TB. This is
especially likely when serology or radiology is unavailable or
inaccessible to the patient due to cost. Even when patients
are correctly diagnosed, the paucity of evidence-based data
to guide aspergilloma treatment in resource-poor settings
makes individualizing care challenging.
Primary aspergilloma is rare and tends to occur in
immunocompromised patients such as those with neutrope-
nia, long-term glucocorticoid use, or AIDS through bronchialinvasion by Aspergillus spp. and subsequent cavitation [7].
Secondary aspergilloma occurs in immunocompetent
patients with previous lung pathology such as TB, sarcoidosis,
lung abscess, bronchogenic cysts, or lung tumor who are
exposed to Aspergillus spores in dry or very dusty environ-
ments, hay barns, or compost sites [8–12]. The most common
pre-existing lung pathology is TB [8,10,13] with time interval
between diagnosis of TB and aspergilloma ranging from
<1 year to 30 years [10].
In the case of our immunocompetent host, his prior his-
tory of TB in 2006 was the primary lung pathology that made
him susceptible to aspergilloma. This initial clinical diagnosis
of smear-negative TB was supported by a 29-kg increase in his
weight and resolution of his constitutional symptoms follow-
ing TB treatment. Chest CT scan in 2013 also demonstrated
bilateral apical post-TB lung fibrosis. It is possible that our
patient was then exposed to Aspergillus conidia during his
frequent desert travels, which resulted in seeding of a
tuberculous cavity. There was a 6-year interval between the
patient’s diagnosis of TB and aspergilloma, which could be
attributed to diagnostic challenges since he had been symp-
tomatic for a 5-year period.
The natural history of aspergilloma is still largely
unknown [3,13]. However, most cases of aspergilloma are
asymptomatic and 10% demonstrate spontaneous resolution
[6,13,14]. Symptoms are nonspecific and include hemoptysis,
cough, chest pain, and fever. Massive hemoptysis, which
occurred in our patient, is an uncommon complication and
is thought to occur as a result of mechanical or endotoxic
irritation vessels or direct invasion by the fungal ball [6].
Development of invasive disease is also a recognized compli-
cation [15].
Previously, the only published guidelines for the diagnosis
and management of aspergilloma were put forth by the Infec-
tious Disease Society of America (IDSA) in 2000 and updated
in 2008. In January 2016, the European Society for Clinical
Microbiology and Infectious Diseases (ESCMID) collaborated
with the European Respiratory Society (ERS) to review recent
data on fungal infections and release new clinical guidelines
for the management of CPA (including aspergilloma) [16].
According to ESCMID/ERS, diagnosis of aspergilloma requires
radiological imaging consistent with aspergilloma, direct
serological or microbiological evidence of Aspergillus spp.,
and exclusion of other diagnoses. Symptoms also need to
have been present for 3 months before the criteria are met
[16].
Diagnosing aspergillomas
Chest radiographs are often the first imaging ordered and
reviewed when there is suspicion for lung pathology. In the
case of aspergilloma, they may show fibrosis (especially in
the upper lung lobes), cavitation, thickening, or a fungal ball
[16]. Fungal ball within a pulmonary cavity is highly sugges-
tive of the diagnosis. A CT scan is preferential for diagnostic
purposes, and two distinct signs may aid in diagnosis. Air
crescent sign is a crescent-shaped air space separating the
fungal ball from the cavity wall. Notably, this may also be
found in Wegener’s granulomatosis, hydatid cyst, hematoma,
and lung abscess [17]. Monod sign, a change in position of the
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occurs in approximately two-thirds of patients [10,17]. Our
patient had fungal ball on chest radiographs (Fig. 1A and B)
as well as on CT scan showing bilateral apical post-TB lung
fibrosis and a thick-walled cavity with a solid intracavity
mass with air crescent sign (Fig. 2A and B). These findings
ultimately allowed for diagnosis of aspergilloma in our
patient.
If imaging is suggestive of aspergilloma, evidence of an
immunological response to Aspergillus spp. or direct evidence
of Aspergillus can help to confirm the diagnosis [16]. Serologi-
cal testing for precipitins [immunoglobulin G (IgG) antibodies
to Aspergillus] allows for definitive diagnosis and will be pre-
sent in >90% of cases [16]. Testing for IgM and IgA antibodies
is not recommended, but IgE may be useful in specific con-
texts [16]. There is also an assay against galactomannan
(GM), a polysaccharide component of the cell walls in
Aspergillus that may be detected in bronchoalveolar lavage
fluid and blood. The sensitivity for GM in bronchoalveolar
lavage has been shown to be much greater than serum GM
[9,18,19]. Moreover, the GM test will be falsely positive in
patients taking piperacillin or tazobactam and its clinical util-
ity has been questioned by some researchers [8]. In some
cases of aspergilloma, antibody or GM testing may be falsely
negative, especially if another species of Aspergillus is
involved or if the patient is taking corticosteroids [6].
The presence of Aspergillus (via microscopy, polymerase
chain reaction assay, or culture) from bronchoscopic or spu-
tum specimens may be consistent with the diagnosis of
aspergilloma, but these investigations alone are not diagnos-
tic as they are not extremely sensitive or specific for aspergil-
loma [16]. Ideally, aspergilloma and TB can be distinguished
by history, serology/respiratory samples, and radiological
differences without lung biopsy [20]. However, biopsy and
video thoracoscopy can also play a role in diagnosis [21].
Our patient did not receive any of these laboratory tests as
they were not available at our hospital, so his aspergilloma
diagnosis was aided by thoracic CT scan. Availability of tests
required for definitive diagnosis of aspergilloma is a common
challenge in resource-poor settings. The tests needed to
thoroughly investigate this differential are often lacking,
and even when available, patients may be unable to afford
them [5,6]. A host of other conditions such as TB, lung tumor,
histoplasmosis, and blastomycosis may also present with
similar symptoms and a well-circumscribed upper lobe lesion
[7,9,11,12], and diagnostic delays may increase morbidity and
mortality. In the developing world, aspergilloma is often
misdiagnosed as TB because clinicians rely heavily on pre-
sumptive diagnoses and empiric treatment. To further
complicate matters, active TB may coexist with aspergilloma
in rare cases [22]. In our patient, the initial diagnosis of asper-
gilloma was likely missed, explaining the patient’s lack of
response to anti-TB medication and worsening symptoms
that ultimately led to massive hemoptysis.
Treatment of aspergillomas
Generally, asymptomatic patients with aspergilloma do not
require treatment and can be monitored for the development
of symptomatic disease. Symptomatic patients are treatedbased on whether they have single or multiple aspergilloma
as well as the severity of their symptoms. Single symptomatic
lesions are best treated by surgical resection [3,10,23]. How-
ever, surgery carries significant risks such as bronchopleural
fistula, massive hemorrhage, empyema, Horner’s syndrome,
and death from respiratory failure [10], and so the benefits
must be weighed carefully against calculated risks. Despite
this, the IDSA and ESCMID/ERS guidelines recommend
surgery for all eligible patients with aspergilloma, especially
those with severe hemoptysis [16,20]. In our patient, surgical
resection was not considered due to availability and cost.
Antifungals can be used as the mainstay of treatment in
cases such as with our patient where surgery is not available
or feasible [3,8]. Although the drug does not penetrate the
cavity of the aspergilloma well [8], some researchers have
found itraconazole to be 60–70% effective in stabilizing or
improving symptoms and arresting progression [5]. Currently,
itraconazole is most widely used [6] but voriconazole and
intralesional amphotericin B can be used for secondary
treatment [11]. It is not clear whether antifungal therapy as
an adjuvant to surgery has a significant impact on postopera-
tive morbidity or long-term survival [12,24]. Radiologic
improvement and resolution rarely occurs in symptomatic
cases.
Conclusion
This case report serves to sensitize physicians of the need to
entertain a broad differential diagnosis in patients presenting
with symptoms of TB, especially in cases where sputum for
AFB is negative, patients appear to have failed standard TB
treatment, or patients have risk factors for developing CPA
such as aspergilloma. Improved access to efficacious antifun-
gals and options for surgical treatments are greatly needed
and will increase patients’ life expectancy and decrease
working days lost to sickness. This report also highlights
the need for affordable and easy-to-use tools to improve case
finding of aspergilloma in developing countries and to
determine its contribution to morbidity and mortality.
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